Lilly, And Novo Nordisk Observe An Endless Market For Weight-Loss Medications
Except for their availability which could prevent Novo Nordisk and Eli Lilly’s explosive sales of their diabetes and weight-loss medications from continuing into the upcoming years. The worldwide obesity medicine boom has mostly benefited these two corporations, driving up their market values and changing expectations for packaged foods, sugary snacks, and nutritional supplements in addition to the…









